Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of Zampilimab in Healthy Participants
NCT04705350Phase 1Completed
- Sponsor
- UCB
- Start
- Jan 2021
- Primary completion
- Jul 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD) and chronic allograft injury (CAI) comparing Zampilimab Cohorts with Placebo (2 arms). Primary endpoints: Incidents of Treatment-Emergent Adverse Events and Maximum Intensity of Treatment-Emergent Adverse Events. Started Jan 2021; status: completed.
02
Drugs
Zampilimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)chronic kidney disease (CKD)chronic allograft injury (CAI)
Beyond the preview
Go deeper on NCT04705350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04705350.